Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its latest attempt to fend off competition from copies of its weight-loss drug.

Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, launched a new advertising campaign on Friday warning patients about off-brand versions of its treatments, saying “they ...

Are you a print subscriber? Activate your account. By Ad Age and Creativity Staff - 14 hours 20 min ago By Garett Sloane - 16 hours 19 min ago By Ad Age Staff - 18 hours 6 min ago By Ad Age Staff ...

One of the "Healthy Skepticism" campaign print ads (Eli Lilly) In a recent interview about another short film that went live during this year’s Grammy Awards and was aimed at improving early ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) has achieved complete skin clearance after three years in 50% of patients with moderate-to-severe atopic dermatitis (AD) in a Phase III trial. The US ...

Novo and Lilly’s campaigns are not limited to advertisements alone, and both companies are trying to raise awareness around obesity through research studies and conferences.

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

As the contentious debate over compounded weight loss drugs continues, Eli Lilly is stepping out with an ad campaign to further stake its claim as a leader in the obesity market. In the national print ...

Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” fourth quarter 2024 investor ...

INDIANAPOLIS — Eli Lilly announced Wednesday the launch of higher doses of Zepbound — and that the company is lowering the price of certain doses. People taking Zepbound, or interested in starting, ...